GlassScriptPhysician profile
Thomas S Nabity
NPI 1306924220
$829.31
in general payments reported to CMS, 2019-2025
14 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $58.61 · 2021: $146 · 2022: $228 · 2024: $96.34 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $192.28 | 2019-2022 | |
| Aerin Medical INC. | $158.54 | 2022-2025 | |
| Stryker Corporation | $114.70 | 2019-2025 | Scopis Ent |
| Intersect Ent, INC. | $65.15 | 2019-2021 | |
| Smith+Nephew, INC. | $58.23 | 2024-2025 | Rf20000, Coblation, Halo |
| Genzyme Corporation | $43.59 | 2021-2022 | |
| Acclarent, INC | $39.29 | 2019-2022 | |
| Kerecis Limited | $34.52 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Welch Allyn | $28.96 | 2021 | |
| Abbvie INC. | $25.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.01 | 2021 | |
| Alk-Abello, INC | $18.40 | 2019 | |
| Amgen INC. | $15.03 | 2022 | |
| Glaxosmithkline, LLC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Nabity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.